• Company
• Celltrion seeks to expand influence in EUR with Remsima SC
• by Hwang, Byung-woo Jul 5, 2024 05:48am

• Policy
• 10th external reference pricing reeval meeting is held
• by Lee, Tak-Sun Jul 5, 2024 05:48am

• Company
• Will the shingles market shift affect NIP?
• by Hwang, Byung-woo Jul 4, 2024 05:52am

• Company
• MBK Partners to acquire Japan pharma for KRW 3 trillion
• by Kim, Jin-Gu Jul 4, 2024 05:52am

• Company
• Camzyos’s reimbursement in KOR will be redeliberated today
• by Eo, Yun-Ho Jul 4, 2024 05:52am

• Policy
• Daewoong·Ildong late entries to the dapagliflozin market
• by Lee, Tak-Sun Jul 4, 2024 05:52am

• Company
• Avastin biosimilars occupy over 40% of Avastin mkt
• by Chon, Seung-Hyun Jul 3, 2024 05:51am

• Company
• KOR, with 12 items, ranks '2nd' in FDA-approved biosimilars
• by Kim, Jin-Gu Jul 3, 2024 05:51am

• Company
• Eliquis generics will soon return to market
• by Kim, Jin-Gu Jul 3, 2024 05:50am

• Company
• New drug 'Aquipta' for migraine available for prescriptions
• by Eo, Yun-Ho Jul 3, 2024 05:50am